Boundless Bio, Inc. (BOLD) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the annual meeting of stockholders held on June 15, 2026. Boundless Bio, Inc., a Delaware corporation listed on the Nasdaq Global Select Market under the symbol BOLD, reported the voting results for two proposals submitted to its security holders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes and does not contain financial performance data.
Material Changes
No material changes to financial operations or business strategy are disclosed in this filing. The primary event reported is the successful election of directors and the ratification of the independent auditor.
Outlook, Risks, and Management Commentary
Management commentary is limited to the reporting of vote tallies. The filing references a definitive proxy statement filed on April 28, 2026, for detailed descriptions of the proposals. No specific risks, contingencies, or unusual items are detailed in this document.
Key Facts for Investors
- Director Election: Both Class II director nominees, James Christensen, Ph.D., and Jennifer Lew, were elected. Significant broker non-votes (5,757,105 each) were recorded alongside votes for and withheld.
- Auditor Ratification: Stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Voting Outcome: Proposal 2 received 15,376,973 votes for, 127,747 votes against, and 52,066 abstentions.
- Emerging Growth Status: The company is identified as an emerging growth company.